WATERTOWN, Massachusetts, June 23, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to the development and commercialization of therapies to improve the lives of patients with serious eye disease, today announced the election of Anthony (Tony) Adamis, MD to its Board of Directors. dr. Adamis is a highly experienced ophthalmology executive with more than 30 years of experience in research and development in the biopharmaceutical industry.
“Dr. Adamis is a pioneer in the discovery and early development of anti-VEGF drugs for the treatment of eye disease and will be a valuable member of our board of directors,” said Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals. “Tony has an outstanding track record of guiding the development of 20 drugs and 25 U.S. Food and Drug Administration approvals, and we look forward to leveraging his expertise as we continue to grow our company and build our leading pipeline, EYP -1901, further developing. , through the clinic for multiple ophthalmic indications.”
“It is my pleasure to welcome Dr. Adamis to the EyePoint Board of Directors,” said Dr. Göran Ando, MD, Chairman of the Board of Directors of EyePoint Pharmaceuticals. “Tony’s scientific and operational experience developing innovative eye therapies from early discovery to commercial stages is uniquely positioned for him to provide valuable input as we work towards EyePoint’s goal of becoming the leader in ocular drug delivery technology . On behalf of the Board of Directors, we are delighted with Tony’s expertise and look forward to working with him.”
dr. Adamis is best known for his co-discovery of the role of vascular endothelial growth factor (VEGF) in eye conditions, including wet age-related macular degeneration (AMD) and diabetic retinopathy. Prior to joining EyePoint’s Board of Directors, Dr. Adamis held several positions at Genentech/Roche, most recently as Senior Vice President, Development Innovation, and led the first FDA-approved drugs for diabetic macular edema and diabetic retinopathy, among others. Prior to that, he was the co-founder, director, president and CEO of Jerini Ophthalmic. dr. Adamis also co-founded EyeTech Pharmaceuticals, which received FDA approval for the first anti-VEGF drug in ophthalmology, and was acquired by OSI Pharmaceuticals in 2005. Currently Dr. Adamis is a senior lecturer in the Department of Ophthalmology at Harvard Medical School. dr. Adamis holds an MD with honors from the University of Chicago, Pritzker School of Medicine, and completed his ophthalmology residency at the University of Michigan and fellowship training at Harvard Medical School. He has a BS in biology from the University of Illinois, Urbana-Champaign.
“I am excited to join EyePoint at this important time as the company is poised to expand its clinical trials for EYP-1901, an intravitreal long-delivery anti-VEGF treatment, for the potential treatment of multiple ophthalmic indications , including wet AMD,” said Dr. Tony Adamis, MD “I look forward to supporting the company’s mission to improve the lives of patients with serious eye conditions and bring innovative products to patients in the United States and around the world.”
dr. Adamis was elected to the Board of Directors by the Company’s shareholders at the Company’s annual meeting held earlier today, along with a number of returning directors.
About EYP-1901
EYP-1901 is being developed as an investigational long-term administration treatment initially in wet age-related macular degeneration, combining a bioerodible formulation of EyePoint’s proprietary Durasert. delivery technology with vorolanib, a tyrosine kinase inhibitor. Positive interim safety and efficacy data from eight months from the ongoing DAVIO Phase 1 clinical trial of EYP-1901 showed no reports of ocular or drug-related systemic SAEs and no dose-limiting toxicities with stable visual acuity and OCT. Furthermore, 53% and 41% of eyes did not require additional anti-VEGF injections until six and nine months, respectively, after a single dose of EYP-1901. Phase 2 clinical trials are planned for wet AMD in the third quarter of 2022 and in diabetic retinopathy in the second half of 2022. Vorolanib is licensed exclusively by Equinox Sciences to EyePoint for the localized treatment of all eye diseases.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company focused on developing and commercializing therapies to help improve the lives of patients with serious eye conditions. The company’s pipeline uses its own Durasert technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained-dose intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Proven Durasert drug delivery platform has been safely delivered to the eyes of thousands of patients through four US FDA-approved products, including YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently being marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIONS LITIGATION ACT OF 1995: To the extent statements in this press release relate to information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds for the offering and other statements identified by words such as “will”, “potentially”, “could”, “may”, “believe”, “intend”, “continue”, “plan”, “expect”, “anticipate”, “estimate”, “may”, other words of similar meaning or the use of future dates. Forward-looking statements naturally involve matters that are uncertain to varying degrees Uncertainties and risks could cause EyePoint’s actual results to differ materially from those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes stock price volatility and uncertainties related to financial markets, the ongoing impact of the COVID-19 pandemic on EyePoint’s operations, the medical community and the global economy, and the impact of general business and economic conditions . More detailed information about these and additional factors that could affect EyePoint’s actual results is described in EyePoint’s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as revised or supplemented by the Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements in this press release speak only as of the date of this press release. EyePoint undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise
Investors:
Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com
Media contact
Amy Phillips
Green room communication
Direct: 412-327-9499
aphillips@greenroompr.com
